Larsen NE - Search Results

1

A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration.

Talvik M, Nordström AL, Larsen NE, Jucaite A, Cervenka S, Halldin C, Farde L. Talvik M, et al. Among authors: larsen ne. Psychopharmacology (Berl). 2004 Sep;175(2):148-53. doi: 10.1007/s00213-004-1802-1. Epub 2004 Mar 6. Psychopharmacology (Berl). 2004. PMID: 15007534 Clinical Trial.

2

The relationship between perphenazine plasma levels and clinical response in acute schizophrenia.

Omérov M, Wistedt B, Bolvig-Hansen L, Larsen NE. Omérov M, et al. Among authors: larsen ne. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(1-2):159-66. doi: 10.1016/0278-5846(89)90013-4. Prog Neuropsychopharmacol Biol Psychiatry. 1989. PMID: 2664884 Clinical Trial.

3

Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice.

Hansen LB, Larsen NE. Hansen LB, et al. Among authors: larsen ne. Psychopharmacology (Berl). 1985;87(1):16-9. doi: 10.1007/BF00431770. Psychopharmacology (Berl). 1985. PMID: 3933033

4

Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose.

Kistrup K, Gerlach J, Aaes-Jørgensen T, Larsen NE. Kistrup K, et al. Among authors: larsen ne. Psychopharmacology (Berl). 1991;105(1):42-8. doi: 10.1007/BF02316862. Psychopharmacology (Berl). 1991. PMID: 1745710

5

Dose-response relationships of perphenazine in the treatment of acute psychoses.

Hansen LB, Larsen NE, Gulmann N. Hansen LB, et al. Among authors: larsen ne. Psychopharmacology (Berl). 1982;78(2):112-5. doi: 10.1007/BF00432245. Psychopharmacology (Berl). 1982. PMID: 6817364

6

Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment.

Hansen LB, Larsen NE. Hansen LB, et al. Among authors: larsen ne. Psychopharmacology (Berl). 1977 Jul 18;53(2):127-30. doi: 10.1007/BF00426481. Psychopharmacology (Berl). 1977. PMID: 408838

7

Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.

Hansen LB, Larsen NE, Vestergård P. Hansen LB, et al. Among authors: larsen ne. Psychopharmacology (Berl). 1981;74(4):306-9. doi: 10.1007/BF00432736. Psychopharmacology (Berl). 1981. PMID: 6794071

8

[Therapy control of perphenazine. 2. Clinical aspects].

Kjeldsen CS, Larsen NE, Kragh-Sørensen P, Andersen E, Brøsen K, Gerholt F, Glue P, Hørder M, Klitgaard NA, Krarup G, et al. Kjeldsen CS, et al. Among authors: larsen ne. Ugeskr Laeger. 1991 Aug 19;153(34):2339-43. Ugeskr Laeger. 1991. PMID: 1897043 Clinical Trial. Danish.

9

Plasma levels of zimelidine and norzimelidine in endogenous depression.

Hansen LB, Thomsen IS, Vestergård P, Larsen NE, Hvidberg EF. Hansen LB, et al. Among authors: larsen ne. Psychopharmacology (Berl). 1980;69(2):157-60. doi: 10.1007/BF00427642. Psychopharmacology (Berl). 1980. PMID: 6450427

10

The practical significance of nortriptyline plasma control. A prospective evaluation under routine conditions in endogenous depression.

Sørensen B, Kragh-Sørensen P, Larsen NE, Hvidberg EF. Sørensen B, et al. Among authors: larsen ne. Psychopharmacology (Berl). 1978 Sep 15;59(1):35-9. doi: 10.1007/BF00428027. Psychopharmacology (Berl). 1978. PMID: 100810 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100 results

Search Page

Filters